What is Metformin Good For?
Metformin is primarily indicated for improving glycemic control in type 2 diabetes mellitus in adults and children ≥10 years old, where it serves as first-line therapy due to its proven reduction in microvascular complications, cardiovascular events, and mortality. 1
Primary FDA-Approved Indication
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in:
- Adults with type 2 diabetes
- Pediatric patients ≥10 years old with type 2 diabetes 1
Maximum daily dose in pediatric patients is 2000 mg 1
Position in Type 2 Diabetes Treatment Algorithm
For patients requiring glucose-lowering therapy without additional cardiovascular, renal, or heart failure considerations, metformin remains the commonly used first-line medication because it is:
- Effective and safe
- Inexpensive and widely available
- Reduces microvascular complications, cardiovascular events, and death
- Weight neutral (does not cause weight gain)
- Does not cause hypoglycemia
- Superior to sulfonylureas in reducing cardiovascular mortality
- More effective than DPP-4 inhibitors for A1C and weight reduction 2
When to Start Metformin
- Initiate when lifestyle modifications alone are insufficient to achieve individualized glycemic goals
- Can be used as monotherapy or in combination with other agents
- Consider dual therapy or more potent agents when A1C is ≥1.5% above goal 2
When NOT to Use Metformin as First-Line
Newer agents (GLP-1 RAs or SGLT2 inhibitors) should be prioritized over metformin in patients with:
- Established atherosclerotic cardiovascular disease (ASCVD)
- Heart failure
- Chronic kidney disease
- High cardiovascular risk indicators 3
Key Safety Considerations and Contraindications
Renal Function
- Contraindicated when eGFR <30 mL/min/1.73 m² 1
- Safe to use when eGFR ≥30 mL/min/1.73 m² 2
- For eGFR 30-45 mL/min/1.73 m², monitor closely due to increased risk of lactic acidosis 2
- Assess renal function more frequently in elderly patients 1
Hepatic Impairment
- Not recommended in patients with hepatic impairment due to association with lactic acidosis 1
Lactic Acidosis Risk
- Extremely rare complication (primarily occurs with eGFR <30 mL/min/1.73 m²)
- Risk increases with acute kidney injury or overdose 2
Vitamin B12 Deficiency
- Associated with increased risk of B12 deficiency and worsening neuropathy symptoms
- Periodic testing of vitamin B12 levels is recommended 2
Gastrointestinal Side Effects Management
The principal side effects are GI-related (bloating, abdominal discomfort, diarrhea). Mitigate by:
- Gradual dose titration
- Using extended-release formulation (once-daily dosing vs. twice-daily immediate-release) 2
Special Populations
Pregnancy
- Limited data suggest no clear association with major birth defects or adverse maternal/fetal outcomes
- May result in ovulation in anovulatory premenopausal women—discuss unintended pregnancy potential 1
Lactation
- Present in human milk at low levels (0.11-1% of maternal weight-adjusted dose)
- Insufficient data on effects on breastfed infant 1
Elderly
- Start at low end of dosing range
- More frequent renal function monitoring required
- Higher risk of lactic acidosis 1
Emerging and Investigational Uses
While metformin has established off-label uses in polycystic ovarian syndrome, gestational diabetes, prediabetes prevention, and adjunct therapy in type 1 diabetes, these are not FDA-approved indications 4. Current investigational uses include cancer prevention, renal protection, Alzheimer's disease, and metabolic dysfunction-associated steatotic liver disease, but these remain experimental and should not guide current clinical practice 4, 5.
Important caveat: Despite recent interest in metformin for peripheral artery disease, a 2026 randomized trial showed no improvement in 6-minute walk distance or walking performance in PAD patients without diabetes—metformin should not be used for this indication 6.